> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alnylam's HELIOS-B Data Challenges Oral Stabilizers in ATTR Cardiomyopathy
- URL: https://bioweek.com/alnylams-helios-b-results-shift-the-standard-of-care-in-attr-cardiomyopathy/
- Published: 2026-07-02T14:00:00.000Z
- Updated: 2026-08-31T10:19:35.000Z
- Description: Phase 3 vutrisiran data demonstrated a 28% reduction in mortality risk, setting up an upstream gene-silencing showdown against Pfizer's incumbent oral blockbuster tafamidis.
- Author: BioWeek
- Tags: Pipeline, Markets

For more than half a decade, the treatment paradigm for transthyretin amyloid cardiomyopathy (ATTR-CM) rested almost exclusively on oral kinetic stabilizers. While stabilizing the circulating TTR tetramer slowed disease progression, it left clinicians searching for therapeutic options capable of halting ongoing amyloid deposition by shutting down mutant protein synthesis at the genetic source.

Topline data from Alnylam Pharmaceuticals' Phase 3 HELIOS-B [trial](https://www.nejm.org/?ref=bioweek.com) confirmed that vutrisiran achieved statistically significant reductions in all-cause mortality and recurrent cardiovascular events across both the overall patient population and the monotherapy subgroup. Administered subcutaneously once every three months, the RNA interference therapeutic showed a 28% reduction in mortality risk compared to placebo, alongside consistent preservation of functional capacity and quality of life scores.

The clinical readout carries substantial commercial ramifications for the rare cardiac disease market. Pfizer's oral stabilizer tafamidis has generated multibillion-dollar annual revenues as the incumbent standard of care. By demonstrating robust clinical benefit in patients already receiving background stabilizer therapy as well as treatment-naive individuals, Alnylam established a compelling rationale for upstream gene silencing.

### Targeting the Source of Amyloid Fibrils

The pathophysiology of ATTR-CM stems from misfolded transthyretin proteins aggregating into insoluble amyloid fibrils within the myocardium. Stabilizers bind the thyroxine-binding sites to prevent tetramer dissociation, but progressive organ damage often continues. In contrast, vutrisiran harnesses catalytic RNA interference to degrade messenger RNA in hepatocytes, reducing serum TTR levels by more than 80%.

Cardiologists participating in the study noted that early intervention yielded the most pronounced separation in event-free survival curves. Patients presenting with early-stage heart failure preserved six-minute walk distance and New York Heart Association functional class significantly longer than historical stabilizer cohorts.

Safety and tolerability remained clean, with adverse event rates comparable between vutrisiran and placebo arms and zero drug-related treatment discontinuations.

### Regulatory Filings and Market Competition

Alnylam submitted supplemental regulatory filings to the U.S. Food and Drug Administration and the European Medicines Agency seeking expanded approval for vutrisiran in cardiomyopathy. The asset is already marketed as Amvuttra for ATTR polyneuropathy, providing an established commercial and manufacturing infrastructure.

Competition in the TTR space continues to accelerate. BridgeBio Pharma is advancing its oral stabilizer acoramidis toward commercial launch, while Ionis Pharmaceuticals and AstraZeneca develop eplontersen in cardiomyopathy. However, the depth of outcome data in HELIOS-B establishes a high clinical benchmark for second-generation therapies entering the clinic.